Summary
Johnson & Johnson (JNJ) filed an 8-K on January 22, 2019, to report its fourth quarter and full year 2018 financial results. The filing includes a press release detailing sales and earnings, as well as supplementary financial data. Investors should review these results to understand the company's recent performance across its diverse business segments, including pharmaceuticals, medical devices, and consumer health. While the 8-K itself is a notification of the release of financial information, the attached press release and supplementary data contain the core performance metrics. Key areas to focus on would be revenue growth, earnings per share, and performance by segment, which provide insight into the operational health and strategic execution of Johnson & Johnson. Investors can use this information to assess the company's ability to meet market expectations and its trajectory for the upcoming fiscal year.
Key Highlights
- 1JNJ announced its Q4 and Full Year 2018 financial results on January 22, 2019.
- 2The 8-K filing includes a press release detailing sales and earnings for the period ended December 30, 2018.
- 3Supplementary financial data, including unaudited comparative statements, is provided.
- 4The filing allows investors to assess the company's performance across its key business segments: Pharmaceuticals, Medical Devices, and Consumer Health.
- 5Investors can use this report to gauge the company's financial health and operational performance at the end of the 2018 fiscal year.
- 6The provided data covers the fourth quarter and the full fiscal year, offering both short-term and long-term performance perspectives.